Used primarily in research settings as a metabolite and prodrug derivative related to deferasirox, deferasirox methyl ester plays a role in the development of iron chelation therapies. It contributes to studies focused on improving bioavailability and pharmacokinetics of iron chelators, which are critical in treating chronic iron overload conditions such as thalassemia and hemochromatosis. Due to its esterified structure, it may exhibit enhanced membrane permeability, making it valuable in probing cellular uptake mechanisms and metabolic conversion to the active parent compound. Its application remains largely confined to preclinical research and analytical reference use rather than direct therapeutic application.